Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 334

1.

Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report.

Massimino M, Stella S, Tirrò E, Consoli ML, Pennisi MS, Puma A, Vitale SR, Romano C, Zammit V, Stagno F, Di Raimondo F, Manzella L.

Oncol Lett. 2019 Sep;18(3):2648-2653. doi: 10.3892/ol.2019.10558. Epub 2019 Jul 4.

2.

Unusual Karyotype in Acute Myelomonocitic Leukemia: A Case Report.

Consoli ML, Romano A, Parrinello NL, Tambè L, Romeo MA, Salemi D, Santoro A, DI Raimondo F.

Anticancer Res. 2019 Aug;39(8):4329-4332. doi: 10.21873/anticanres.13599.

PMID:
31366525
3.

Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report.

Massimino M, Stella S, Tirrò E, Consoli ML, Pennisi MS, Puma A, Vitale SR, Romano C, Zammit V, Stagno F, DI Raimondo F, Manzella L.

Anticancer Res. 2019 Jul;39(7):3949-3954. doi: 10.21873/anticanres.13548.

PMID:
31262926
4.

Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22).

Tirrò E, Massimino M, Stella S, Zammit V, Consoli ML, Pennisi MS, Vitale SR, Romano C, Pirosa MC, Martino E, DI Gregorio S, Puma A, DI Raimondo F, Manzella L, Stagno F.

Anticancer Res. 2019 Jul;39(7):3893-3899. doi: 10.21873/anticanres.13540.

PMID:
31262918
5.

Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network.

Conticello C, Romano A, Del Fabro V, Martino EA, Calafiore V, Sapienza G, Leotta V, Parisi MS, Markovic U, Garibaldi B, Leotta S, Cotzia E, Innao V, Mannina D, Neri S, Musso M, Scalone R, Cangialosi C, Acquaviva F, Cardinale G, Merenda A, Maugeri C, Uccello G, Poidomani M, Longo G, Carlisi M, Tibullo D, Di Raimondo F.

J Clin Med. 2019 Jun 19;8(6). pii: E877. doi: 10.3390/jcm8060877.

6.

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.

Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, Nagler A, Hajek R, Offidani M, Liberati AM, Sonneveld P, Cavo M, Corradini P, Boccadoro M.

Haematologica. 2019 Jun 20. pii: haematol.2019.219139. doi: 10.3324/haematol.2019.219139. [Epub ahead of print]

7.

Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma.

Offidani M, Boccadoro M, Di Raimondo F, Petrucci MT, Tosi P, Cavo M.

Curr Hematol Malig Rep. 2019 Jun;14(3):187-196. doi: 10.1007/s11899-019-00507-x. Review.

PMID:
31077067
8.

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.

Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F.

Int J Mol Sci. 2019 May 6;20(9). pii: E2226. doi: 10.3390/ijms20092226.

9.

Colony-Forming Cell Assay Detecting the Co-Expression of JAK2V617F and BCR-ABL1 in the Same Clone: A Case Report.

Tirrò E, Stella S, Massimino M, Zammit V, Pennisi MS, Vitale SR, Romano C, Di Gregorio S, Puma A, Di Raimondo F, Stagno F, Manzella L.

Acta Haematol. 2019;141(4):261-267. doi: 10.1159/000496821. Epub 2019 Apr 9.

PMID:
30965317
10.

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.

Bernardi S, Malagola M, Zanaglio C, Polverelli N, Dereli Eke E, D'Adda M, Farina M, Bucelli C, Scaffidi L, Toffoletti E, Deambrogi C, Stagno F, Bergamaschi M, Franceschini L, Abruzzese E, Divona MD, Gobbi M, Di Raimondo F, Gaidano G, Tiribelli M, Bonifacio M, Cattaneo C, Iurlo A, Russo D.

Cancer Med. 2019 May;8(5):2041-2055. doi: 10.1002/cam4.2087. Epub 2019 Apr 4.

11.

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.

Vendramini E, Bomben R, Pozzo F, Benedetti D, Bittolo T, Rossi FM, Dal Bo M, Rabe KG, Pozzato G, Zaja F, Chiarenza A, Di Raimondo F, Braggio E, Parikh SA, Kay NE, Shanafelt TD, Del Poeta G, Gattei V, Zucchetto A.

Leukemia. 2019 Aug;33(8):2111-2115. doi: 10.1038/s41375-019-0444-6. Epub 2019 Mar 14. No abstract available.

PMID:
30872781
12.

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53.

Tirrò E, Massimino M, Romano C, Pennisi MS, Stella S, Vitale SR, Fidilio A, Manzella L, Parrinello NL, Stagno F, Palumbo GA, La Cava P, Romano A, Di Raimondo F, Vigneri PG.

Front Oncol. 2019 Feb 18;9:57. doi: 10.3389/fonc.2019.00057. eCollection 2019.

13.

Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.

Romano A, Parrinello NL, Chiarenza A, Motta G, Tibullo D, Giallongo C, La Cava P, Camiolo G, Puglisi F, Palumbo GA, Di Raimondo F.

Br J Haematol. 2019 May;185(3):468-479. doi: 10.1111/bjh.15801. Epub 2019 Feb 15.

PMID:
30768678
14.

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.

Bringhen S, Mina R, Petrucci MT, Gaidano G, Ballanti S, Musto P, Offidani M, Spada S, Benevolo G, Ponticelli E, Galieni P, Cavo M, Di Toritto TC, Di Raimondo F, Montefusco V, Palumbo A, Boccadoro M, Larocca A.

Haematologica. 2019 Aug;104(8):1640-1647. doi: 10.3324/haematol.2018.208272. Epub 2019 Feb 7.

15.

α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload.

Camiolo G, Tibullo D, Giallongo C, Romano A, Parrinello NL, Musumeci G, Di Rosa M, Vicario N, Brundo MV, Amenta F, Ferrante M, Copat C, Avola R, Li Volti G, Salvaggio A, Di Raimondo F, Palumbo GA.

Int J Mol Sci. 2019 Jan 31;20(3). pii: E609. doi: 10.3390/ijms20030609.

16.

Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations.

Girmenia C, Cavo M, Offidani M, Scaglione F, Corso A, Di Raimondo F, Musto P, Petrucci MT, Barosi G.

Blood Rev. 2019 Mar;34:84-94. doi: 10.1016/j.blre.2019.01.001. Epub 2019 Jan 9. Review.

PMID:
30683446
17.

Successful coronary artery bypass graft surgery in severe congenital factor VII deficiency: Perioperative treatment with pd-factor VII concentrate.

Giuffrida G, Nicolosi D, Giuffrida A, Rapisarda C, Calafiore V, Giuffrida A, Di Raimondo F.

Haemophilia. 2019 Mar;25(2):e135-e137. doi: 10.1111/hae.13657. Epub 2018 Dec 27. No abstract available.

PMID:
30589157
18.

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.

Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N.

Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.

PMID:
30502854
19.

Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.

Pirosa MC, Leotta S, Cupri A, Stella S, Martino EA, Scalise L, Sapienza G, Calafiore V, Mauro E, Spadaro A, Vigneri P, Di Raimondo F, Milone G.

Chemotherapy. 2018;63(4):220-224. doi: 10.1159/000492941. Epub 2018 Oct 29.

20.

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).

Musto P, Simeon V, Cascavilla N, Falcone A, Petrucci MT, Cesini L, Di Raimondo F, Conticello C, Ria R, Catalano L, Salvatore D, Mastrullo L, Gagliardi A, Villani O, Pietrantuono G, D'Arena G, Mansueto G, Bringhen S, Genuardi M, Di Renzo N, Reddiconto G, Fragasso A, Caravita T, Scapicchio D, Marziano G, Boccadoro M, Mangiacavalli S, Corso A.

Ann Hematol. 2019 Feb;98(2):361-367. doi: 10.1007/s00277-018-3524-1. Epub 2018 Oct 23.

PMID:
30353388
21.

Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.

Sorrenti V, Pittalà V, Romeo G, Amata E, Dichiara M, Marrazzo A, Turnaturi R, Prezzavento O, Barbagallo I, Vanella L, Rescifina A, Floresta G, Tibullo D, Di Raimondo F, Intagliata S, Salerno L.

Eur J Med Chem. 2018 Oct 5;158:937-950. doi: 10.1016/j.ejmech.2018.09.048. Epub 2018 Sep 17.

PMID:
30261468
22.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M.

JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

23.

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.

Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI, Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S, Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG, Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del Poeta G, Cortelezzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foà R, Morabito F.

Eur J Haematol. 2018 Jul 24. doi: 10.1111/ejh.13149. [Epub ahead of print] No abstract available.

PMID:
30039576
24.

Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases.

Morabito F, Shanafelt TD, Gentile M, Reda G, Mauro FR, Rossi D, Di Renzo N, Molica S, Angrilli F, Chiarenza A, Cutrona G, Chaffee KG, Parikh SA, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Cortelezzi A, Gaidano G, Di Raimondo F, Fais F, Foà R, Neri A, Ferrarini M.

Am J Hematol. 2018 Sep;93(9):E216-E219. doi: 10.1002/ajh.25206. Epub 2018 Jul 30. No abstract available.

25.

Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib.

Barbagallo I, Giallongo C, Volti GL, Distefano A, Camiolo G, Raffaele M, Salerno L, Pittalà V, Sorrenti V, Avola R, Di Rosa M, Vanella L, Di Raimondo F, Tibullo D.

Mol Neurobiol. 2019 Feb;56(2):1451-1460. doi: 10.1007/s12035-018-1133-6. Epub 2018 Jun 10.

PMID:
29948946
26.

PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.

Romano A, Parrinello NL, La Cava P, Tibullo D, Giallongo C, Camiolo G, Puglisi F, Parisi M, Pirosa MC, Martino E, Conticello C, Palumbo GA, Di Raimondo F.

Expert Rev Mol Diagn. 2018 Jul;18(7):675-683. doi: 10.1080/14737159.2018.1470929. Epub 2018 May 3.

PMID:
29707981
27.

Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.

Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366. doi: 10.1007/s00432-018-2641-5. Epub 2018 Apr 19.

PMID:
29675792
28.

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.

Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A, Morabito F.

Leukemia. 2018 Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6. Epub 2018 Mar 20. No abstract available.

PMID:
29588545
29.

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.

Massimino M, Stella S, Tirrò E, Romano C, Pennisi MS, Puma A, Manzella L, Zanghì A, Stagno F, Di Raimondo F, Vigneri P.

Mol Cancer. 2018 Feb 19;17(1):56. doi: 10.1186/s12943-018-0805-1. Review.

30.

Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.

Romano A, Parrinello NL, Vetro C, Chiarenza A, Cerchione C, Ippolito M, Palumbo GA, Di Raimondo F.

Ann Hematol. 2018 Jun;97(6):1009-1018. doi: 10.1007/s00277-018-3276-y. Epub 2018 Feb 14.

PMID:
29442162
31.

The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents.

Romano A, Laura Parrinello N, Cerchione C, Letizia Consoli M, Parisi M, Calafiore V, Martino E, Conticello C, Di Raimondo F, Alberto Palumbo G.

Blood Cancer J. 2017 Dec 15;7(12):649. doi: 10.1038/s41408-017-0019-6. No abstract available.

32.

Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.

Giallongo C, Parrinello NL, La Cava P, Camiolo G, Romano A, Scalia M, Stagno F, Palumbo GA, Avola R, Li Volti G, Tibullo D, Di Raimondo F.

J Cell Mol Med. 2018 Feb;22(2):1070-1080. doi: 10.1111/jcmm.13326. Epub 2017 Dec 8.

33.

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.

Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M.

Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.

34.

Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.

Visani G, Ferrara F, Di Raimondo F, Loscocco F, Fuligni F, Paolini S, Zammit V, Spina E, Rocchi M, Visani A, Piccaluga PP, Isidori A.

Leuk Res. 2017 Nov;62:77-83. doi: 10.1016/j.leukres.2017.09.019. Epub 2017 Sep 25.

35.

NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, Martorelli D, Bravin V, D'Agaro T, Rossi FM, Bomben R, Santinelli E, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Poeta G, Rossi D, Gaidano G, Dal Bo M, Gattei V, Zucchetto A.

Leukemia. 2018 Mar;32(3):654-662. doi: 10.1038/leu.2017.296. Epub 2017 Sep 22.

PMID:
28935990
36.

Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia.

Bulian P, Bomben R, Bo MD, Zucchetto A, Rossi FM, Degan M, Pozzo F, Bittolo T, Bravin V, D'Agaro T, Cerri M, Chiarenza A, Chaffee KG, Condoluci A, D'Arena G, Spina M, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Poeta GD, Gaidano G, Shanafelt TD, Gattei V.

Haematologica. 2017 Nov;102(11):e443-e446. doi: 10.3324/haematol.2017.170340. Epub 2017 Jul 27. No abstract available.

37.

NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.

D'Agaro T, Bittolo T, Bravin V, Dal Bo M, Pozzo F, Bulian P, Rossi FM, Zucchetto A, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Bomben R.

Br J Haematol. 2018 Aug;182(4):597-602. doi: 10.1111/bjh.14843. Epub 2017 Jul 12. No abstract available.

PMID:
28699643
38.

Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia.

Bittolo T, Pozzo F, Bomben R, D'Agaro T, Bravin V, Bulian P, Rossi FM, Zucchetto A, Degan M, Macor P, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Haematologica. 2017 Aug;102(8):e305-e309. doi: 10.3324/haematol.2016.162594. Epub 2017 May 26. No abstract available.

39.

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.

Romano A, Giallongo C, La Cava P, Parrinello NL, Chiechi A, Vetro C, Tibullo D, Di Raimondo F, Liotta LA, Espina V, Palumbo GA.

Front Pharmacol. 2017 Apr 26;8:204. doi: 10.3389/fphar.2017.00204. eCollection 2017.

40.

NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.

Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi FM, Zucchetto A, Tissino E, Degan M, D'Arena G, Di Raimondo F, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Leukemia. 2017 Nov;31(11):2407-2415. doi: 10.1038/leu.2017.90. Epub 2017 Mar 21.

PMID:
28321119
41.

The Heme Oxygenase System in Hematological Malignancies.

Li Volti G, Tibullo D, Vanella L, Giallongo C, Di Raimondo F, Forte S, Di Rosa M, Signorelli SS, Barbagallo I.

Antioxid Redox Signal. 2017 Aug 20;27(6):363-377. doi: 10.1089/ars.2016.6735. Epub 2017 May 19. Review.

PMID:
28257621
42.

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.

Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, Di Nicola M, Patti C, Mulé A, Zanni M, Zoli V, Billio A, Piccin A, Negri G, Castellino C, Di Raimondo F, Ferreri AJ, Benedetti F, La Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Chilosi M, Bruna R, Tabanelli V, Pileri S, Masciulli A, Delaini F, Boschini C, Rambaldi A.

J Clin Oncol. 2016 Nov 20;34(33):4015-4022. doi: 10.1200/JCO.2016.67.2980. Epub 2016 Oct 31.

43.

Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.

Conticello C, Parisi M, Romano A, Calafiore V, Ancora F, La Fauci A, Consoli ML, Di Raimondo F.

Future Oncol. 2017 Feb;13(5s):3-6. doi: 10.2217/fon-2016-0368.

PMID:
28116941
44.

Pomalidomide: when expectations are understated.

Di Raimondo F, Conticello C.

Future Oncol. 2017 Feb;13(5s):1-2. doi: 10.2217/fon-2016-0559. No abstract available.

45.

Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.

Gentile M, Magarotto V, Offidani M, Musto P, Bringhen S, Teresa Petrucci M, Gay F, Larocca A, Uccello G, Petrungaro A, Vigna E, Greco R, Grazia Recchia A, Tripepi G, Ria R, Di Raimondo F, Palumbo A, Morabito F.

Am J Hematol. 2017 Mar;92(3):244-250. doi: 10.1002/ajh.24621. Epub 2017 Jan 23.

46.

Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.

Ruggieri M, Praticò AD, Serra A, Maiolino L, Cocuzza S, Di Mauro P, Licciardello L, Milone P, Privitera G, Belfiore G, Di Pietro M, Di Raimondo F, Romano A, Chiarenza A, Muglia M, Polizzi A, Evans DG.

Acta Otorhinolaryngol Ital. 2016 Oct;36(5):345-367. doi: 10.14639/0392-100X-1093. Review.

47.

Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.

Giuffrida G, Lombardo R, Di Francesco E, Parrinello L, Di Raimondo F, Fiumara A.

J Med Case Rep. 2016 Nov 8;10(1):315.

48.

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.

Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, Capodanno I, Mannina D, Salvucci M, Antolino A, Marasca R, Musso M, Crugnola M, Impera S, Trabacchi E, Musolino C, Cavazzini F, Mineo G, Tosi P, Tomaselli C, Rizzo M, Siragusa S, Fogli M, Ragionieri R, Zironi A, Soverini S, Martinelli G, Cavo M, Vigneri P, Stagno F, Rosti G, Baccarani M.

Am J Hematol. 2017 Jan;92(1):82-87. doi: 10.1002/ajh.24591. Epub 2016 Nov 18.

49.

The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.

Molica S, Shanafelt TD, Giannarelli D, Gentile M, Mirabelli R, Cutrona G, Levato L, Di Renzo N, Di Raimondo F, Musolino C, Angrilli F, Famà A, Recchia AG, Chaffee KG, Neri A, Kay NE, Ferrarini M, Morabito F.

Am J Hematol. 2016 Nov;91(11):1090-1095. doi: 10.1002/ajh.24493. Epub 2016 Aug 8.

50.

Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM).

Tibullo D, Caporarello N, Giallongo C, Anfuso CD, Genovese C, Arlotta C, Puglisi F, Parrinello NL, Bramanti V, Romano A, Lupo G, Toscano V, Avola R, Brundo MV, Di Raimondo F, Raccuia SA.

Nutrients. 2016 Oct 1;8(10). pii: E611.

Supplemental Content

Loading ...
Support Center